Thursday, March 28, 2019

Insilico Medicine to present at NVIDIA webinar

Insilico Medicine to present its latest research on a live NVIDIA webinar
Thursday, March 28, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery on a live NVIDIA webinar on April 11, 2019, at 11:00 AM Pacific time. 
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, get medications to patients faster and help patients comply with their treatments. Moreover, supported by new insights from AI, the new pharma landscape will be a patient-centered world where medicine comes to the individual rather than the other way around.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, AI helps more drugs to be discovered and come to market quickly. 
The presentation will focus on the applications of deep adversarial networks and reinforcement learning for molecular de novo design and biomarker research. It will also briefly cover Insilico's drug discovery pipeline and platforms and present applications of machine learning to every step of preclinical drug discovery.
"We are happy to present our work on a live episode of NVIDIA webinar. The topic of AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
"Machine learning techniques, such as deep generative models and reinforcement learning optimization, play a pivotal role in developing new pharmaceuticals. I am very excited to share our vision and latest results with the audience of the upcoming NVIDIA webinar," said Alex Zhebrak, CTO of Insilico Medicine, Inc.
"I am fascinated by the opportunity to present some of our recent research on a live NVIDIA webinar episode. At Insilico, we are working on comprehensive and robust biomarkers of aging developed using deep learning and blood biochemistry, transcriptomics, and even imaging data to be able to track the effectiveness of the various interventions we are developing," said Polina Mamoshina, a senior research scientist at Insilico Medicine.
The NVIDIA webinar will go live on the 11th of April 2019, at 11 AM PT.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 
For further information, images or interviews, please contact:
Contact: Klug Gehilfe 
ai@pharma.ai
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. 
Posted by at No comments:

Wednesday, March 27, 2019

Dr. Anne Bertolotti to present at the 6th Aging Research for Drug Discovery Forum in Basel

Monday, March 25, 2019 - Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Anne Bertolotti, Ph.D., FMedSci., Neurobiology Division MRC Laboratory of Molecular Biology, at the 6th Aging Research, Drug Discovery, and AI Forumduring the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.
Dr. Anne Bertolotti will give a talk titled "Power and benefit of selective phosphatase inhibition for neurodegenerative diseases" presenting approaches aimed at helping cells to survive protein quality control failures, which can be useful to prevent protein misfolding diseases, including the devastating neurodegenerative diseases.
The deposition of misfolded proteins is a defining feature of many age-dependent human diseases, including the increasingly prevalent neurodegenerative diseases. Why misfolding-prone proteins accumulate in aged cells remains largely unclear. Cells normally strive to ensure that proteins get correctly folded and have powerful and sophisticated protein quality control mechanisms, to maintain protein homeostasis under adverse conditions. However, with age, the cellular defence systems against misfolded proteins gradually fail, leading to the accumulation of misfolded proteins with devastating consequences for cells and organisms.
In principle, improving the cells' ability to deal with misfolded proteins should represent a generic approach to reduce pathology in diverse protein misfolding diseases. The MRC Laboratory of Molecular Biology has identified powerful strategies to help cells survive when protein quality control fails, implementing some of these strategies in mice. Exploiting the current knowledge on protein quality control systems, a small drug-like molecule that safely boosts the natural defence system against misfolded proteins, has been identified. 
"The small molecules we have identified selectively inhibit a regulatory subunit of a serine/threonine phosphatase controlling the termination of a proteostatic pathway, an interesting finding because phosphatases were previously thought to be undruggable. We have expanded on this idea and developed assays to selectively inhibit regulatory subunits of phosphatases. The assays are versatile and in principle, generically applicable to any phosphatases. This work has broad relevance because there are hundreds of phosphatases that could be inhibited using the same paradigm consisting of targeting their regulatory subunits. This opens up a broad range of possibilities to manipulate cellular function for therapeutic benefit," said Anne Bertolotti, FMedSci., Neurobiology Division MRC Laboratory of Molecular Biology
"Over the last 5 years, the "Aging & Drug Discovery" and "AI for Healthcare" forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Aging, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019. 
"We are delighted to announce the talk from Professor Anne Bertolotti, MRC Laboratory of Molecular Biology, Cambridge. Professor Bertolotti has vastly contributed to our mechanistic understanding of pathological protein aggregation in neurodegeneration. Particularly, her revolutionary discoveries revealing phosphatases as druggable targets may help in the future to find new pharmacological interventions for age-related human diseases. We are therefore extremely excited to welcome Professor Anne Bertolotti at the Aging, Drug Discovery and Artificial Intelligence meeting in Basel," said Dr. Daniela Bakula, University of Copenhagen.
"The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019. 
###
Contact: Ola Popova
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
About Basel Life 2019 
Aging Research for Drug Discovery Forum description 
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet. 
Conference Official Website: https://www.basellife.org/2019.html
About LMB
The MRC Laboratory of Molecular Biology (LMB) is a world-class research laboratory, dedicated to understanding important biological processes at the molecular level - with the goal of using this knowledge to tackle major problems in human health and disease.
The LMB is one of the birthplaces of modern molecular biology. Many techniques were pioneered at the laboratory, including DNA sequencing, methods for determining the three-dimensional structure of proteins and the development of monoclonal antibodies.
LMB official website: https://www2.mrc-lmb.cam.ac.uk/
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.com/
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
Posted by at No comments:

New insights into genetics of fly longevity

Moskalev Lab published a new study on the influence of pro-longevity gene Gclc on age-associated transcriptomic changes in flies
Monday, March 25 2019, - Alexey Moskalev, Ph.D., Head of the Laboratory of Molecular Radiobiology and Gerontology Institute of Biology, and co-authors from the Institute of biology of Komi Science Center of RAS, Engelgard's Institute of molecular biology, involved in the study of the aging mechanisms and longevity of model animals announce the publication of a scientific article titled: "The Neuronal Overexpression of Gclc in Drosophila melanogaster Induces Life Extension With Longevity-Associated Transcriptomic Changes in the Thorax" in  Frontiers in Genetics - a leading open science platform.
"The new study sheds light on longevity-associated transcriptome changes and will be useful for assessing the effects of genetic interventions that prevent premature aging," said Alexey Moskalev, PhD, head of the laboratory of Geroprotector and radioprotector technologies.
Aging inevitably leads to progressive organ dysfunction, creating a major problem for modern medicine that seems to have required many parallel tissue-specific interventions slowing down aging of the whole organism. Sarcopenia is primarily a disease of the elderly, characterized by the loss of skeletal muscle function and mass. A number of studies showed that muscle tissue undergoes sufficient alterations in gene expression patterns, during aging in mammals and flies. 
"Alexey Moskalev is one of the rising young stars in biogerontology and this study further advances our understanding of aging in flies. Aging is not only a fly problem but a process that concerns everyone on the planet regardless of race, sex or nationality. It is a global challenge that should be addressed through massive international collaborations and Dr. Moskalev is helping build a community of scientists working in longevity biotechnology", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine and adjunct professor at the Buck Institute for Research on Aging. 
One of the major factors contributing to the decline of muscular function may be the decrease in antioxidant protection by glutathione. To prove this hypothesis, Alexey Moskalev, jointly with other scientists, investigated the effect of neuronal overexpression of the pro-longevity gene Gclc on age-related transcriptome changes in the thorax of Drosophila melanogaster. Previously, the authors showed that overexpression of this gene, encoding a cysteine ligase catalytic subunit, led to lifespan increase and decline of the spontaneous locomotor activity of flies. This study demonstrated 58 differentially expressed genes induced by Gclc overexpression involved in a variety of pathways of metabolism, such as Drug metabolism, Metabolism of xenobiotics by cytochrome P450, Carbohydrate metabolism. Also, changes in expression of genes related to the immune system, circadian rhythmicity, and downregulation of genes involved in proteolysis have been shown.
###
For further information, images or interviews, please contact:
Alexey Moskalev 
moskalev1976@gmail.com
About the Institute of biology of Komi Science Center of RAS
The Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences (IB Komi SC UB RAS) was founded in 1962. The Institute is the largest academic research centre of the East European part of Russia, with biology and ecology as two primary areas of research. The Institute consists of six departments and four laboratories, the Zoological museum, the Botanical garden and the Herbarium (SYKO). The main fields of research include the study of biodiversity, structural and functional organization, stability and productivity of taiga and tundra ecosystems, biological effects of ionizing radiation and other physico-chemical factors on cells, living organisms and natural ecosystems; problems of radiation and ecological genetics, as well as the development of methods for monitoring, bioindication; creation of inventories and databases of biological resources of the European North-East with the use of remote sensing and GIS technologies.
The official website: https://ib.komisc.ru/en/
Please follow the link below to read the article: https://www.frontiersin.org/articles/10.3389/fgene.2019.00149/full
Posted by at No comments:

Monday, March 25, 2019

Dr. Johan Auwerx to present at the 6th Aging Research for Drug Discovery Forum in Basel

Friday, March 22, 2019 - Today Insilico Medicine, an artificial intelligence company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Dr. Johan Auwerx, M.D., Ph.D., Professor at the Ecole Polytechnique Fédérale in Lausanne, Switzerland, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.

Dr. Johan Auwerx will give a talk titled "A novel approach for NAD boosting" presenting a new scientific method to boost NAD+ content by stimulating its de novo biosynthesis.
Nicotinamide adenine dinucleotide (NAD*) has recently evolved from a single oxidoreductase cofactor to being an essential cosubstrate for a wide range of regulatory proteins including the sirtuins, a family of NAD*-dependent protein deacylases. Beneficial effects of increased NAD+ levels and subsequently enhanced sirtuin activity on mitochondrial homeostasis, organismal metabolism and lifespan have now been well established across different species and thus stimulated the interest in approaches aiming to raise NAD+ content. 
"We show that the enzyme α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) plays a crucial role in the control of the intracellular NAD+ levels. By using both genetic and pharmacological tools we found that reduction of ACMSD activity boosts de novo NAD+ synthesis. Through its impact on cellular NAD+ levels and SIRT1 activity, ACMSD inhibition promotes mitochondrial function, but, most importantly, possesses a high therapeutic potential for preservation of hepatic and renal function from injury, given the restricted ACMSD expression to these tissues. As a case in point, we have developed potent and selective ACMSD inhibitors, which provided striking protection against non-alcoholic fatty liver disease and acute kidney injury in mice," said Dr. Johan Auwerx, M.D., Ph.D., Professor at the Ecole Polytechnique Fédérale in Lausanne, Switzerland.
"Over the last 5 years, the "Aging & Drug Discovery" and "AI for Healthcare" forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Aging, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019. 
"It is our great pleasure to present Professor Johan Auwerx, EPFL Lausanne, as a speaker at the Aging, Drug Discovery and Artificial Intelligence meeting in Basel. Professor Auwerx has been critical for our understanding of aging particularly focusing on NAD metabolism in aging. He is a global leader in the field and has contributed with many seminal discoveries linking loss of NAD to the aging process and has further described how we can target NAD to extend mammalian lifespan. It is therefore an unquestionable honor that Professor Auwerx has chosen to join our meeting and we look forward to his exciting talk," said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
"The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019. 
###
Contact: Ola Popova
ola@pharma.ai
Website: http://insilico.com/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
About Basel Life 2019 
Aging Research for Drug Discovery Forum description 
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet. Conference Official Website: https://www.basellife.org/2019.html
About EPFL
EPFL is Europe's most cosmopolitan technical university. It welcomes students, professors and collaborators of more than 120 nationalities. EPFL has both a Swiss and international vocation and focuses on three missions: teaching, research and innovation.
EPFL collaborates with an important network of partners, including other universities and colleges, secondary schools and gymnasiums, political circles and the general public, with the aim of having a real impact on society.
EPFL official website: https://www.epfl.ch/en/home/
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.com/
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.

Posted by at No comments:

Thursday, March 21, 2019

Insilico to present at the CHIC Conference

Insilico Medicine to present at the 10th Anniversary CHIC Conference
Thursday, March 21, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery and productive longevity at the 10th Anniversary CHIC Conference in Shanghai, March 26-28. 
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in transforming pharmaceutical industry, making the hunt for new medicines quicker and more effective. The presentation will cover the recent progress in the end-to-end drug discovery pipeline development at Insilico Medicine and recent advances in the generative adversarial networks (GANs) and reinforcement learning (RL) used for generation of novel chemistry, and identification of novel biological targets.
"We are happy to present our latest research at the 10th Anniversary CHIC Conference, which gathers the leading longevity leaders. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The CHIC Conference is the event of the year to meet and learn about upcoming Chinese healthcare companies and industry trends, with senior executives from over 65 of the industry's most influential companies who will share their insights through keynote presentations and candid panel discussions. The event is held in Shanghai, on March 26-28, 2019. 
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 
For further information, images or interviews, please contact:
Contact: Klug Gehilfe 
ai@pharma.ai
Official website of the conference: 
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:

Tuesday, March 19, 2019

Machine learning scientists to collaborate on AI-powered drug discovery

Machine learning scientists to collaborate on a research topic on AI-powered drug discovery

Monday, March 18, 2019 - The advances in Artificial intelligence (AI) have successfully propagated into the many areas such as computer vision, speech recognition, and natural language processing. AI is now rapidly propagating into the areas requiring substantial domain expertise such as biology, chemistry promising to speed up, improving the success rates, and lower the cost of drug discovery and drug development. 
The laboratories of Jianfeng Pei at Peking University and Alex Zhavoronkov at Insilico Medicine partner with Frontiers in Pharmacology, a leading open science platform on the research topic "AI for drug discovery and development". This Research Topic will highlight the most recent advances and perspectives of all kinds of artificial intelligence technologies used to accelerate and improve pharmaceutical R&D.
"Artificial intelligence is rapidly propagating into life sciences resulting in a wave of academic publications in the field of AI-powered drug discovery, a plethora of startups developing new strategies and pursuing innovative business models to transform pharmaceutical research and development. The pharmaceutical industry is also strengthening its internal capabilities in this area by centralizing the previously segregated data sources, hiring data scientists and investing in infrastructure," said Jianfeng Pei, Ph.D., Peking University, Beijing.
"The integration of machine learning with ever-more extensive biological data-sets promises to accelerate advancement in the field of human health in an unprecedented manner, not least to assist in tackling the 'failure to fail' in current drug development pipelines, previously highlighted by our Translational Pharmacology section Chief Editor Prof Alastair Stewart. We in Frontiers in Pharmacology are excited to partner with Dr. Zhavoronkov and Dr. Pei, to develop a broad-scope, open-access article collection aiming to reflect and catalyze leading-edge developments in this field globally," said Brian Boyle, Journal Development Manager, Frontiers in PharmacologyJournal.
The applications of AI in drug discovery are very broad and can be classified into several areas:
    1. Knowledge discovery and hypothesis generation 
    2. Target identification
    3. Compound generation
    4. Virtual screening
    5. ADME/Tox
    6. Predicting the outcomes of clinical trials and clinical trials enrollment
    7. Personalized medicine
    8. Real-world evidence analysis and actuarial pharmacology
The advent of artificial intelligence in the pharmaceutical industry is expected to enable the countries that did not previously engage in early-stage drug discovery and innovative medicine to leapfrog years of pharma R&D and contribute to the global push for better health. With 1.4 billion people and the government push for innovative medicines, China is expected to become the major force in the pharmaceutical industry. The authors hope that trade wars do not impact this important field. Cancer, Alzheimer's and other diseases do not discriminate by the nation. Until there is a clear set of cures, a trade war in biotechnology R&D is equivalent to a war on all people. Advances in biomedicine require massive international collaborations, diversity, and data sharing initiatives. 
"We are very happy to partner with the leading scientist in China and globally, Dr. Jianfeng Pei of the Peking University on this research topic and welcome scientists from all over the world to collaborate and contribute to it", said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The Research Topic covers new AI algorithms and (or) applications in a wide range of areas such as drug target identification, systems biology, pharmacogenomics, network pharmacology, chemical property prediction, synthesis planning, molecular design and generation, protein-ligand interaction, drug-target interaction network, drug-related knowledge graphs, big data analysis for drug information, and image recognition. This Research Topic will highlight the most recent advances and perspectives on all kinds of artificial intelligence technologies used in drug design.
In this Research Topic, the authors welcome Perspective and Policy papers proposing the paths for the development of innovative medicines using AI and accelerating pharma R&D in the developed and developing countries.
Contact: Ola Popova
ola@pharma.ai
Website: http://insilico.com/
About Frontiers Research Topics
Frontiers' Research Topics are peer-reviewed article collections around themes of cutting-edge research. Defined, managed, and led by renowned researchers, they unite the world's leading experts around the hottest topics in research, stimulating collaboration and accelerating science.
Managed and disseminated on Frontiers' customized Open Science platform, these collections are free to access and highly visible, increasing the discoverability, readership, and citations of your research.
Research Topics spotlight the most specialized communities and enable leading researchers to edit article collections Over 200,000 authors contributed to Research Topics
Research Topic articles have received more than 280,000,000 views and downloads 
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:
Subscribe to: Posts (Atom)